Skip to main content
SpringerLink
Log in

The Role of the Food and Drug Administration in Medical Therapy for Ulcerative Colitis

  • Chapter
  • First Online:
Medical Therapy of Ulcerative Colitis

  • 1269 Accesses

Abstract

Ulcerative colitis (UC) affects approximately 1 in 400 people internationally, with a higher prevalence in the Western hemisphere, although more recently incidence and prevalence rates have been rising in the rest of the world, particularly in Asia. The majority of UC patients are prescribed with medication for induction or maintenance of remission. In addition to standard therapies, recent developments in immunology have identified novel therapeutic pathways and biologic agents to treat inflammatory bowel disease. There are currently 11 drugs and biologic agents (including prednisolone, sulfasalazine, balsalazide, budesonide MMX, infliximab, adalimumab, golimumab, and different preparations of mesalamines) approved by the Food and Drug Administration (FDA) to treat UC. At present, there are 145 registered clinical trials evaluating therapeutics for managing adult UC, including drugs, biologic agents, and clinical tools for therapeutic monitoring of treatment response and disease activity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–25.

    Article  CAS  PubMed  Google Scholar 

  2. Thia KT, Loftus Jr EV, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103(12):3167–82.

    Article  PubMed  Google Scholar 

  3. Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol. 2004;99(4):650–5.

    Article  PubMed  Google Scholar 

  4. DeMets D, Califf R, Dixon D, Ellenberg S, Fleming T, Held P, et al. Issues in regulatory guidelines for data monitoring committees. Clin Trials. 2004;1(2):162–9.

    Article  PubMed  Google Scholar 

  5. Hamburg MA. Shattuck lecture. Innovation, regulation, and the FDA. N Engl J Med. 2010;363(23):2228–32.

    Article  CAS  PubMed  Google Scholar 

  6. Hanauer SB. Another one bites the dust. Nat Clin Pract Gastroenterol Hepatol. 2005;2(10):435.

    Article  PubMed  Google Scholar 

  7. Meadows M. Bringing real life to the table. Patient reps help FDA review products. FDA Consum. 2002;36(1):10–1.

    Google Scholar 

  8. Lesko LJ, Salerno RA, Spear BB, Anderson DC, Anderson T, Brazell C, et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J Clin Pharmacol. 2003;43(4):342–58.

    Article  CAS  PubMed  Google Scholar 

  9. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–28.

    Article  CAS  PubMed  Google Scholar 

  10. Flieger K. FDA finds new ways to speed treatment to patients. FDA Consum. 1993;27(8):14–8.

    CAS  PubMed  Google Scholar 

  11. Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7.

    Article  CAS  PubMed  Google Scholar 

  12. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65 e1-3.

    Article  CAS  PubMed  Google Scholar 

  13. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.

    Article  CAS  PubMed  Google Scholar 

  14. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10(9):1002–7. quiz e78.

    Article  PubMed  Google Scholar 

  15. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–104.

    Article  CAS  PubMed  Google Scholar 

  16. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215–20.

    Article  PubMed  Google Scholar 

  17. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58(1):108–17.

    Article  CAS  PubMed  Google Scholar 

  18. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008;358(13):1354–61.

    Article  CAS  PubMed  Google Scholar 

  19. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13(8):1024–30.

    Article  PubMed  Google Scholar 

  20. Lahiff C, Kane S, Moss AC. Drug development in inflammatory bowel disease: the role of the FDA. Inflamm Bowel Dis. 2011;17(12):2585–93.

    Article  PubMed  Google Scholar 

  21. Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials. 2007;8:17.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs. 2008;68(8):1089–103.

    Article  CAS  PubMed  Google Scholar 

  23. Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9(6):483–9 e3.

    Article  PubMed  Google Scholar 

  24. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–201.

    Article  CAS  PubMed  Google Scholar 

  25. Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis–additional results from two controlled studies. Aliment Pharmacol Ther. 2011;34(7):747–56.

    Article  CAS  PubMed  Google Scholar 

  26. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5(5):477–83.

    Article  PubMed  Google Scholar 

  27. Lahiff C, Safaie P, Awais A, Akbari M, Gashin L, Sheth S, et al. The Crohn’s disease activity index (CDAI) is similarly elevated in patients with Crohn’s disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013;37(8):786–94.

    Article  CAS  PubMed  Google Scholar 

  28. Stidham RW, Higgins PD. Value of mucosal assessment and biomarkers in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4(3):285–91.

    Article  CAS  PubMed  Google Scholar 

  29. Kelly CP. Fecal microbiota transplantation—an old therapy comes of age. N Engl J Med. 2013;368(5):474–5.

    Article  CAS  PubMed  Google Scholar 

  30. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(7):1079–87.

    Article  PubMed  Google Scholar 

  31. Stremmel W, Hanemann A, Ehehalt R, Karner M, Braun A. Phosphatidylcholine (lecithin) and the mucus layer: evidence of therapeutic efficacy in ulcerative colitis? Dig Dis. 2010;28(3):490–6.

    Article  PubMed  Google Scholar 

  32. Mullard A. Hearing shines spotlight on biosimilar controversies. Nat Rev Drug Discov. 2010;9(12):905–6.

    Article  CAS  PubMed  Google Scholar 

  33. Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, et al. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005;11 Suppl 1:S22–8.

    Article  PubMed  Google Scholar 

  34. Travis S. Does it all ADA up? Adalimumab for ulcerative colitis. Gut. 2011;60(6):741–2.

    Article  PubMed  Google Scholar 

  35. Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol. 2008;6(6):654–60. quiz 04.

    Article  CAS  PubMed  Google Scholar 

  36. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23. quiz 24.

    Article  PubMed  Google Scholar 

  37. Hennessy S, Strom BL. PDUFA reauthorization - drug safety’s golden moment of opportunity? N Engl J Med. 2007;356(17):1703–4.

    Article  CAS  PubMed  Google Scholar 

  38. Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691–9.

    PubMed  Google Scholar 

  39. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–24.

    Article  CAS  PubMed  Google Scholar 

  40. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61(6):918–32.

    Article  CAS  PubMed  Google Scholar 

  41. Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2012;62:1122–30.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Unit, Mater Hospital, Whitty Building 4th Floor, Eccles St., Dublin 7, Ireland

    Conor Lahiff M.D.

  2. Division of Gastroenterology, Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA

    Conor Lahiff M.D., Alan C. Moss M.D. & Adam S. Cheifetz M.D.

Authors
  1. Conor Lahiff M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan C. Moss M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adam S. Cheifetz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Conor Lahiff M.D. .

Editor information

Editors and Affiliations

  1. Gastroenterology Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

    Gary R. Lichtenstein

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lahiff, C., Moss, A.C., Cheifetz, A.S. (2014). The Role of the Food and Drug Administration in Medical Therapy for Ulcerative Colitis. In: Lichtenstein, G. (eds) Medical Therapy of Ulcerative Colitis. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1677-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1677-1_2

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1676-4

  • Online ISBN: 978-1-4939-1677-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation